Piper Sandler Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $40.00

Key Points

• Piper Sandler has raised the price target for Supernus Pharmaceuticals from $36.00 to $40.00, maintaining a "neutral" rating, which indicates potential downside from the company's previous close.
• Supernus Pharmaceuticals' stock currently has an average rating of "Moderate Buy" with a consensus target price of $43.00, following multiple upgrades by analysts.
• Insider trading activity has been notable, with CEO Jack A. Khattar selling 140,000 shares recently, leading to an 11.96% decrease in their ownership stake.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) had its target price increased by research analysts at Piper Sandler from $36.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the specialty pharmaceutical company's stock. Piper Sandler's price target points to a potential downside of 11.73% from the company's previous close.

SUPN has been the topic of several other reports. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Stock Down 0.1%

SUPN traded down $0.06 during trading on Friday, hitting $45.32. The company had a trading volume of 12,213 shares, compared to its average volume of 636,408. The company has a market capitalization of $2.54 billion, a PE ratio of 39.32 and a beta of 0.74. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $45.60. The firm's 50-day moving average price is $36.37 and its 200 day moving average price is $33.90.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jack A. Khattar sold 140,000 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares of the company's stock, valued at $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 179,606 shares of company stock valued at $7,617,005 over the last three months. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in SUPN. MetLife Investment Management LLC raised its position in Supernus Pharmaceuticals by 4.7% in the fourth quarter. MetLife Investment Management LLC now owns 30,822 shares of the specialty pharmaceutical company's stock worth $1,115,000 after acquiring an additional 1,394 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Supernus Pharmaceuticals by 39.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,163 shares of the specialty pharmaceutical company's stock valued at $114,000 after purchasing an additional 889 shares during the period. Northern Trust Corp raised its position in shares of Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after purchasing an additional 110,867 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $388,000. Finally, Comerica Bank grew its stake in Supernus Pharmaceuticals by 71.0% during the fourth quarter. Comerica Bank now owns 37,548 shares of the specialty pharmaceutical company's stock valued at $1,358,000 after acquiring an additional 15,585 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.